New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape

Mittal, Deepak, Gubin, Matthew M., Schreiber, Robert D. and Smyth, M. J. (2014) New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Current Opinion in Immunology, 27 1: 16-25. doi:10.1016/j.coi.2014.01.004


Author Mittal, Deepak
Gubin, Matthew M.
Schreiber, Robert D.
Smyth, M. J.
Title New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape
Journal name Current Opinion in Immunology   Check publisher's open access policy
ISSN 0952-7915
1879-0372
Publication date 2014-04-01
Year available 2014
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/j.coi.2014.01.004
Open Access Status Not Open Access
Volume 27
Issue 1
Start page 16
End page 25
Total pages 10
Place of publication Kidlington, Oxford, United Kingdom
Publisher Elsevier
Language eng
Abstract The principles of cancer immunoediting have set the foundations for understanding the dual host-protective and tumor sculpting actions of immunity on cancer and establishing the basis for novel individualized cancer immunotherapies. During cancer immunoediting, the host immune system shapes tumor fate in three phases through the activation of innate and adaptive immune mechanisms. In the first phase, Elimination, transformed cells are destroyed by a competent immune system. Sporadic tumor cells that manage to survive immune destruction may then enter an Equilibrium phase where editing occurs. The Escape phase represents the third and final phase of the process, where immunologically sculpted tumors begin to grow progressively, become clinically apparent and establish an immunosuppressive tumor microenvironment. This review focuses on important recent developments that have enhanced our understanding of each phase of the cancer immunoediting process, summarizes the discovery of new predictive and prognostic biomarkers and discusses development of novel and objectively effective cancer immunotherapies.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2015 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 255 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 258 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 04 Mar 2014, 10:16:31 EST by System User on behalf of School of Medicine